Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions
Hypophosphatasia
Interventions
DRUG

asfotase alfa

This is an observational study and no intervention will be administered. All participants will be treated by their physician in accordance with standard of care. All medications are commercially available and will be used as directed by the treating physician.

Trial Locations (1)

34685

Xcenda, LLC, Palm Harbor

Sponsors
All Listed Sponsors
collaborator

Xcenda, LLC

UNKNOWN

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY